Work

[Analysis of the efficacy and safety profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of patients with chronic hepatitis C with failed DAAs therapy].

Year: 2024

Type: other

Abstract: SOF/VEL/VOX is a safe and effective salvage treatment option for chronic hepatitis C patients who have failed DAAs therapy, and may be particularly beneficial to refractory populations infected with genotype 3 and combined with cirrhosis.

Source: PubMed

DOI: 10.3760/cma.j.cn501113-20240822-00380

Authors: Y Guo, S T Zhao, Y Zhu, C Yang, J P Li, L H Zhang, C M Yang, H G Xiong, D Zhang, G J Tian, B H Gao, L Guo, J Xia

Institutions: Army Medical University, Southwest Hospital, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guizhou Provincial People's Hospital, Guangdong Provincial Hospital of Chinese Medicine, Beihai People's Hospital

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4407800696

Cites:

Cited by:

Related to: 10